APC-3000—HFA Inhaled Nasal Steroid
If approved, the APC-3000 will be an HFA inhaled nasal steroid for the treatment of seasonal and perennial allergic rhinitis. With the discontinuation of CFCs as propellants, this market has moved from gas-propelled steroids to aqueous-propelled steroids.
Because several classes of patients (the elderly and the young) have difficulty using the aqueous-delivered products, Adamis believes there is an important and unmet need to reintroduce gas-propelled inhaled nasal steroids. Adamis aims to help populations that have difficulty with aqueous-delivered products by using steroids that already exist and are well known by both the FDA and prescribing physicians. Adamis will use steroids that are established in the medical field but off patent, and couple them with an environmentally friendly HFA (a gas that has been cleared by the FDA). This strategy reduces the risk of developing a new product.
Potential Indication: Allergic Rhinitis
Allergic rhinitis is an allergic inflammation of the nasal airways. It occurs when an allergen, such as pollen, dust or animal dander is inhaled by an individual with a sensitized immune system.